Free access to KiinOS for groundbreaking research

Free access to KiinOS for groundbreaking research

Free access to KiinOS for groundbreaking research

1 year of full KiinOS platform access

1 year of full KiinOS platform access

For PhD researchers, non-profits, and academic labs

For PhD researchers, non-profits, and academic labs

No-cost, just great science

No-cost, just great science

Monthly feedback sessions with the Kiin team

Monthly feedback sessions with the Kiin team

One year of free KiinOS access for academic and nonprofit research teams.

What it is

Most labs have more data than they can actually use. The papers are there, the datasets exist, the results from last year's experiments sit in someone's drive. The hard part is connecting all of it quickly enough to decide what to do next.

KiinOS is where your team runs literature reviews, bioinformatics, and target discovery in one place. It keeps a record of what's been done, by who, and what came out of it. So if one person finds a promising target and someone else has relevant data, the platform connects those results and suggests what to pursue next.

The Pioneer Programme gives selected research teams one year of full access, plus:

  • Onboarding to map your research workflow into the platform

  • Regular check-ins with our science team

  • Technical support throughout

Why we're running it

Discovery gets slow when insight is stuck between people and tools. A postdoc finds a promising target. A colleague has relevant expression data. A paper from six months ago supports the hypothesis. None of it is connected, so the decision takes weeks instead of hours.

We want to work with teams who have a real scientific question and see how much faster that process gets when everything lives in one place.

Who this is for

Research teams in academia or nonprofits who:

  • Are working on early discovery or translational research

  • Have a specific scientific problem they're trying to solve faster

  • Are working across complex evidence (datasets, literature, experiments)

  • Want to move faster without adding headcount or learning to code

Example use cases: target identification, small molecule discovery strategy, biomarker discovery, disease area mapping, cross-dataset interpretation, evidence mapping across publications and internal findings.

What teams have told us

  • "What would have taken me 3 weeks, it did in 30 minutes."

  • "I can now run RNAseq without being a bioinformatician. Before I had to ask colleagues."

  • "I feel confident I can do bioinformatics analysis even if I am not a bioinformatician, which is very empowering for me."

What this isn't

  • A funding grant or stipend

  • An AI training course

  • A replacement for lab infrastructure

  • A fit for projects requiring patient-level sensitive data or large-scale raw data ingestion without a defined question

Data and IP

  • No patient-level or clinical data required

  • No large data transfer needed

  • We do not train on your data

  • ISO 27001 compliant infrastructure

  • All IP stays with your institution

  • In most cases, no complex procurement process is needed

Timeline

  • Applications open: May 2026

  • Deadline: August 2026

  • Cohort announced: September 2026

  • Programme starts: September 2026

Part of a wider network

Selected teams join the Kiin Bio Weekly community, a publication read by ~1,000 researchers, founders, and operators in AI and drug discovery. We share tools, interviews, and analysis each week. Teams can also get visibility through case studies or interviews where relevant.

Explore Kiin Bio Weekly → https://newsletter.kiin.bio/

FAQ

Do we need to transfer sensitive data? No.

Is there a stipend? No. The programme provides platform access plus scientific and technical support.

Who owns the IP? Your institution retains all IP.

Can multiple lab members participate? Yes. We welcome full lab applications.

Is this only for academic institutions? No. Nonprofit research organisations working on discovery and translational research are also eligible.